Key Highlights

• TSX:BHC - Bausch Health Companies Inc. gained approximately 7.42% on 26 June 2026.

• Investors remained encouraged by continued operational execution across key business segments.

• Ongoing debt reduction efforts continued to improve confidence in the company's long-term financial position.

• Stable demand across pharmaceuticals and eye-health products supported sentiment.

• Healthcare stocks attracted renewed buying as investors rotated toward defensive growth sectors.

• Investors continue monitoring future earnings, debt management initiatives and product portfolio expansion.

Why Did TSX:BHC - Bausch Health Companies Inc. Rise Today?

Bausch Health was among the strongest performers within the Canadian healthcare sector as investors responded positively to improving fundamentals and continued confidence in management's strategy to strengthen the balance sheet while growing core pharmaceutical operations.

Although healthcare companies remain influenced by broader market sentiment, investors increasingly focused on company-specific improvements, including stronger operating performance, disciplined cost management and continued efforts to reduce leverage. These factors helped improve confidence that the company is making steady progress in its long-term turnaround strategy.

The healthcare sector also benefited from renewed defensive positioning as investors sought companies with resilient demand characteristics amid ongoing macroeconomic uncertainty.

Why Are Investors Paying Attention to Bausch Health?

Bausch Health has spent recent years reshaping its business following significant restructuring efforts. Management has prioritised improving profitability, generating stronger cash flow and reducing debt while continuing to invest in its core pharmaceutical portfolio.

The company operates across several healthcare categories, including prescription medicines, gastroenterology, dermatology, neurology and eye health. This diversified portfolio provides exposure to multiple healthcare markets rather than relying on a single product.

Investors have increasingly rewarded consistent operational execution and financial discipline as the company continues strengthening its long-term competitive position.

How Is the Business Performing?

The company continues focusing on revenue stability, operating efficiency and cash generation.

Management has prioritised disciplined capital allocation while improving margins and supporting investment in strategic product categories. Investors remain encouraged by efforts to optimise the product portfolio, enhance commercial execution and strengthen long-term financial flexibility.

The ability to generate recurring cash flow remains one of the most important factors supporting investor confidence.

What Is Supporting the Healthcare Sector?

Healthcare remains one of the more defensive sectors during periods of economic uncertainty.

Demand for prescription medicines generally remains resilient regardless of broader economic cycles. At the same time, ageing populations, increasing healthcare spending and continued pharmaceutical innovation continue supporting long-term industry growth.

Canadian healthcare companies have also benefited from renewed institutional interest as investors diversify away from more cyclical industries.

How Could Global Macro and Geopolitical Events Affect Bausch Health?

Developments involving the United States, Iran, Israel and the broader Middle East continue influencing overall market volatility through energy prices and inflation expectations.

While Bausch Health has limited direct exposure to geopolitical events, broader market uncertainty often encourages investors to increase allocations toward defensive sectors such as healthcare.

Lower interest-rate expectations also tend to support healthcare valuations by improving financing conditions and increasing the attractiveness of stable cash-generating businesses.

What Are Investors Watching Next?

Investors will continue monitoring quarterly earnings, debt reduction progress, new product launches, regulatory developments, operating margins and cash flow generation.

Future updates regarding capital allocation, refinancing initiatives and portfolio optimisation are also expected to remain important catalysts.

How Does the Technical Picture Look?

Following today's advance, technical momentum improved as buying interest strengthened.

Higher trading volumes suggested improved investor participation. If the stock maintains support above recent breakout levels, sentiment could remain constructive. However, healthcare stocks can still experience volatility around earnings announcements and regulatory developments.

How Does Valuation Look?

Despite recent gains, many investors continue valuing Bausch Health based on its improving balance sheet and future earnings potential.

Continued debt reduction, stable revenue growth and improving profitability could support further valuation improvement over time, while execution risks remain an important consideration.

What Is the Bull Case?

The bullish case centres on continued debt reduction, stronger cash generation, expanding profitability, successful commercial execution and improving investor confidence in the company's long-term turnaround strategy.

A stable healthcare demand environment and disciplined financial management could continue supporting sentiment.

What Is the Bear Case?

The bearish case focuses on leverage, regulatory risks, pricing pressure within pharmaceutical markets, product competition and the possibility that earnings growth slows if market conditions become more challenging.

Execution remains essential for maintaining investor confidence.

What Are the Key Risks?

Key risks include regulatory changes, patent challenges, competitive pressure, pricing reforms, higher financing costs, product performance, litigation risk and broader market volatility.

How Does Bausch Health Perform on ESG?

The company continues strengthening governance, product quality, patient access and environmental sustainability initiatives while maintaining a focus on responsible manufacturing and compliance.

Healthcare companies increasingly face investor scrutiny regarding governance standards, supply-chain management and product accessibility, making ESG execution an important long-term consideration.

What Is the Short-, Medium- and Long-Term Outlook?

In the short term, investor sentiment remains supported by improving operational execution and favourable sector rotation toward healthcare.

Over the medium term, continued debt reduction and earnings growth are likely to remain the primary valuation drivers.

From a long-term perspective, sustained portfolio optimisation, innovation and disciplined capital allocation could strengthen the company's competitive position, provided management continues delivering consistent operational performance.

Final Investment Conclusion

Bausch Health continues progressing through a multi-year transformation focused on improving profitability, strengthening its balance sheet and generating sustainable cash flow. Today's share-price strength reflects growing confidence that management's strategic priorities are producing measurable results.

While regulatory, competitive and financial risks remain, the company's diversified healthcare portfolio, defensive business characteristics and continued operational improvements leave investors focused on future earnings execution rather than historical challenges.